Potential role of circulating miR-21 in the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis

References

• Villanueva A, Longo DL. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450–1462.
   PubMed Web of Science ®Google Scholar
• International Agency for Research on Cancer. World Health Organization. Cancer today. Available from: https://gco.iarc.fr/today/home
   Google Scholar
• Jemal A, Ward EM, Johnson CJ, et al. Annual report to the nation on the status of cancer, 1975-2014, featuring survival. J Natl Cancer Inst. 2017;9:109.
   Google Scholar
• Sagnelli E, Macera M, Russo A, et al. Epidemiological and etiological variations in hepatocellular carcinoma. Infection. 2020;48(1):7–17.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–2917.
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
   PubMed Web of Science ®Google Scholar
• Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604.
   PubMed Web of Science ®Google Scholar
• Huguet C, Stipa F, Gavelli A. Primary hepatocelular cancer: western experience. In: Blumgart LH, editor. Surgery of the liver and biliary tract. New York: Churchill Livingstone; 1996. p. 1365–1369.
   Google Scholar
• Chedid MF, Kruel CR, Pinto MA, et al. Hepatocellular carcinoma: diagnosis and surgical management. ABCD, Arq Bras Cir Dig. 2017;30(4):272–278
   PubMed Web of Science ®Google Scholar
• Liu AM, Yao TJ, Wang W, et al. Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open. 2012;2(2):e000825.
   PubMed Web of Science ®Google Scholar
• Gramantieri L, Fornari F, Callegari E, et al. MicroRNA involvement in hepatocellular carcinoma. J Cell Mol Med. 2008;12(6a):2189–2204.
   PubMed Web of Science ®Google Scholar
• Famei Q, Zhou A, Yan L, et al. The diagnostic value of PIVKA-II, AFP, AFP-L3, CEA, and their combinations in primary and metastatic hepatocellular carcinoma. J Clin Lab Anal. 2020;34(5):e23158.
   PubMed Web of Science ®Google Scholar
• Tomimaru Y, Eguchi H, Nagano H, et al. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol. 2012;56(1):167–175.
   PubMed Web of Science ®Google Scholar
• Oka H, Tamori A, Kuroki T, et al. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology. 1994;19(1):61–66.
   PubMed Web of Science ®Google Scholar
• Iqbal MA, Arora S, Prakasam G, et al. MicroRNA in lung cancer: role, mechanisms, pathways and therapeutic relevance. Mol Aspects Med. 2019;70:3–20.
   PubMed Web of Science ®Google Scholar
• Yang Z, Miao R, Li G, et al. Identification of recurrence related microRNAs in hepatocellular carcinoma after surgical resection. Int J Mol Sci. 2013;14(1):1105–1118.
   PubMed Web of Science ®Google Scholar
• Koberle V, Kronenberger B, Pleli T, et al. Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer. 2013;49(16):3442–3449.
   PubMed Web of Science ®Google Scholar
• Gu H, Guo X, Zou L, et al. Upregulation of microRNA-372 associates with tumor progression and prognosis in hepatocellular carcinoma. Mol Cell Biochem. 2013;375(1–2):23–30.
   PubMed Web of Science ®Google Scholar
• Cao LQ, Yang XW, Chen YB, et al. Exosomal miR-21 regulates the TETs/PTENp1/PTEN pathway to promote hepatocellular carcinoma growth: mol cancer. 2019;18(1):148. erratum in. Mol Cancer. 2020;19(1):59.
   PubMed Web of Science ®Google Scholar
• Chen S, Yang C, Sun C, et al. miR-21-5p suppressed the sensitivity of hepatocellular carcinoma cells to cisplatin by targeting FASLG. DNA Cell Biol. 2019 8; 38(8): 865–873.
   PubMed Web of Science ®Google Scholar
• Guo X, Lv X, Lv X, et al. Circulating miR-21 serves as a serum biomarker for hepatocellular carcinoma and correlated with distant metastasis. Oncotarget. 2017;8(27):44050–44058.
   PubMedGoogle Scholar
• Kmet LM, Lee RC, Cook LS. Standard quality assessment criteria for evaluating primary research papers from a variety of fields. Edmonton: Alberta Heritage Foundation for Medical Research; 2004;1–22. Available from: https://www.ihe.ca/advanced-search/standard-quality-assessment-criteria-for-evaluating-primaryresearch-papers-from-a-variety-of-fields
   Google Scholar
• Lee J, Kim KW, Choi SH, et al. Systematic review and meta-analysis of studies that assess the accuracy of diagnostic tests: a practical review for clinical researchers - part II. statistical methods of meta-analysis. Korean J Radiol. 2015;16(6):1188–1196.
   PubMed Web of Science ®Google Scholar
• Harbord RM, Egger M, Sterne JAC. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med. 2006;25(20):3443–3457.
   PubMed Web of Science ®Google Scholar
• Kim KW, Lee J, Choi SH, et al. Systematic review and meta-analysis of studies evaluating diagnostic test accuracy: a practical review for clinical researchers-part I. general guidance and tips. Korean J Radiol. 2015;16(6):1118–1175.
   Web of Science ®Google Scholar
• Egger M, Davey Smith G, Phillips AN. Meta-analysis: principles and procedures. Br Med J. 1997;315(7121):1533–1537.
   PubMed Web of Science ®Google Scholar
• Yang M, Wei S, Zhao H, et al. The role of miRNA125b in the progression of hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2021;45(5):101712.
   PubMed Web of Science ®Google Scholar
• Luo P, Wu S, Yu Y, et al. Current status and perspective biomarkers in AFP negative HCC: towards screening for and diagnosing hepatocellular carcinoma at an earlier stage. Pathol Oncol Res. 2019;26(2):599–603.
   PubMed Web of Science ®Google Scholar
• Zhao T, Jia L, Li J, et al. Heterogeneities of site-specific N-Glycosylation in HCC tumors with low and high AFP concentrations. Front Oncol. 2020;10:496.
   PubMed Web of Science ®Google Scholar
• Liu HW, Cheng L, Cao DK, et al. Suppression of miR-21 expression inhibits cell proliferation and migration of liver cancer cells by targeting phosphatase and tensin homolog (PTEN). Med Sci Monit. 2018;24:3571–3577.
   PubMed Web of Science ®Google Scholar
• Masoudi MS, Mehrabian E, Mirzaei H. MiR-21: a key player in the pathogenesis of glioblastoma. J Cell Biochem. 2018;119(2):1285–1290.
   PubMed Web of Science ®Google Scholar
• Zhang C, Liu K, LI, et al. miR-21: a gene of dual regulation in breast cancer. Int J Oncol. 2016;48(1):161–172.
   PubMed Web of Science ®Google Scholar
• Falzone L, Scola L, Zanghi A, et al. Integrated analysis of colorectal cancer microRNA datasets: identification of microRNAs associated with tumor development. Aging (Albany NY). 2018;10(5):1000–1014.
   PubMedGoogle Scholar
• Falzone L, Lupo G, Rosa GRM, et al. Identification of new microRNAs and their diagnosis and prognostic significance in oral cancer. Cancer. 201911(5):610.
   Google Scholar
• Feng YH, Tsao CJ. Emerging role of microRNA-21 in cancer. Biomed Rep. 2016;5(4):395–402.
   PubMed Web of Science ®Google Scholar
• McCubrey JA, Fitzgerald TL, Yang LV, et al. Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells. Oncotarget. 2017;8(8):14221–14250.
   PubMedGoogle Scholar
• Yang CH, Yue J, Pfeffer SR, et al. MicroRNA-21 promotes glioblastoma tumorigenesis by down-regulating insulin-like growth factor-binding protein-3 (IGFBP3). J Biol Chem. 2014;289(36):25079–25087.
   PubMed Web of Science ®Google Scholar
• Lakomy R, Sana J, Hankeova S, et al. MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients. Cancer Sci. 2011;102(12):2186–2190.
   PubMed Web of Science ®Google Scholar
• Schetter AJ, Leung SY, Sohn JJ, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. Jama. 2008;299(4):425–436.
   PubMed Web of Science ®Google Scholar
• Mollaei H, Safaralizadeh R, Rostami Z. MicroRNA replacement therapy in cancer. J Cell Physiol. 2019;234(8):12369–12384.
   PubMed Web of Science ®Google Scholar
• Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 2010;9(10):775–789.
   PubMed Web of Science ®Google Scholar
• Sato APS, Koizumi IK, Faria NOS, et al. Mortality trend due to Hepatitis B and C in the city of São Paulo, 2002–2016. Rev Saude Publica. 2020;54:124. https://www.scielosp.org/article/rsp/2020.v54/124/pt/
   PubMed Web of Science ®Google Scholar
• Ly KN, Xing J, Klevens RM, et al. Causes of death and characteristics of decedents with viral hepatitis, United States, 2010. Clin Infect Dis. 2014;58(1):40–49.
   PubMed Web of Science ®Google Scholar
• Qu J, Yang J, Chen M, et al. MicroRNA-21 as a diagnostic marker for hepatocellular carcinoma: a systematic review and meta-analysis. Pak J Med Sci. 2019;35(5):1466–1471.
   PubMed Web of Science ®Google Scholar
• Xu J, Wu C, Che X, et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog. 2011;50(2):136–142. Epub 2010 Dec 10. PMID: 21229610.
   PubMed Web of Science ®Google Scholar
• Yin H, Peng X, Ren P, et al. MicroRNAs as a novel class of diagnostic biomarkers in detection of hepatocellular carcinoma: a meta-analysis. Tumor Biol. 2014;35(12):12317–12326.
   PubMedGoogle Scholar
• Maxwell GL, Shoji Y, Darcy K, et al. MicroRNAs in endometrial cancers from black and white patients. Am J Obstet Gynecol. 2015;212:191.e1–10.
   PubMed Web of Science ®Google Scholar
• Lu M, Kong X, Wang H, et al. A novel microRNAs expression signature for hepatocellular carcinoma diagnosis and prognosis. Oncotarget. 2017;8(5):8775–8784.
   PubMedGoogle Scholar
• Powell MA, Mutch DG, Rader JS, et al. Ribosomal DNA methylation in patients with endometrial carcinoma: an independent prognostic marker. Cancer. 2002;94(11):2941–2952.
   PubMed Web of Science ®Google Scholar
• Namkung J Statistical Methods for Identifying Biomarkers from miRNA Profiles of Cancers. Methods Mol Biol. 2019;1882:261–286.
   PubMedGoogle Scholar
• Liu CJ, Fu X, Xia M, et al. miRNASNP-v3: a comprehensive database for SNPs and disease-related variations in miRNAs and miRNA targets. Nucleic Acids Res. 2021;49:1276–1281.
   PubMed Web of Science ®Google Scholar
• Shen S, Lin Y, Yuan X, et al. Biomarker MicroRNAs for diagnosis, prognosis and treatment of hepatocellular carcinoma: a functional survey and comparison. Sci Rep. 2016;5(6):38311.
   Google Scholar
• Nagy Á, Lánczky A, Menyhárt O, et al. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep. 2018 Jun 15;8(1):9227.
   PubMed Web of Science ®Google Scholar
• Parizadeh SM, Jafarzadeh-Esfehani R, Ghandehari M, et al. MicroRNAs as potential diagnostic and prognostic biomarkers in hepatocellular carcinoma. Curr Drug Targets. 2019;20(11):1129–1140.
   PubMed Web of Science ®Google Scholar
• Chedid MF, Kruel CRP, Pinto MA, et al. Hepatocellular carcinoma: diagnosis and operative management. Arq Bras Cir Dig. 2017;30(4):272–278.
   PubMed Web of Science ®Google Scholar
• Liao Q, Han P, Huang Y, et al. Potential role of circulating microRNA-21 for hepatocellular carcinoma diagnosis: a meta-analysis. PLoS One. 2015 Jun 26;10(6):e0130677.
   PubMed Web of Science ®Google Scholar
• Yan SR, Liu ZJ, Yu S, et al. Investigation of the value of miR-21 in the diagnosis of early stage HCC and its prognosis: a meta-analysis. Genet Mol Res. 2015 Sep 28;14(3):11573–11586.
   PubMed Web of Science ®Google Scholar
• Fiorino S, Bacchi-Reggiani ML, Visani M, et al. MicroRNAs as possible biomarkers for diagnosis and prognosis of hepatitis B- and C-related-hepatocellular-carcinoma. World J Gastroenterol. 2016 Apr 21;22(15):3907–3936.
   PubMed Web of Science ®Google Scholar